Skip to main content

CVS HEALTH Corp guidance

  • CVS · NYSE
  • Retail
  • Health Care Services
  • S&P 500
$88.59−0.85%Close 16 Nov 2026 · Market value $110.4B

In its results release of 4 Nov 2026 (Q3 FY2026), CVS HEALTH Corp gave 2 forecasts in figures, among them EPS (gaap) of at least $6.98 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · GAAPFY2026At least $6.98GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04
EPS · AdjustedFY2026At least $8.20Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10

Source: the company's earnings release.

Guidance against results above 1 · within 0 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026At least $400.0BGiven once—To come
EPS · GAAPFY2026At least $6.98Raised 3 times—To come
EPS · AdjustedFY2026At least $8.20Raised 3 times—To come
Operating income · GAAPFY2026$13.26B to $13.60BGiven once—To come
Operating income · AdjustedFY2026$15.07B to $15.41BGiven once—To come
Operating cash flowFY2026At least $10.00BGiven once—To come
EPS · AdjustedFY2025$6.60 to $6.70Raised twice$6.75Above the range

CVS in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.